Angiogenesis is critical for the growth and metastasis of triple-negative breast cancer (TNBC) and its inhibition reduces the risk of progression of metastatic TNBC. In this study, we investigated that LYG-202, a flavonoid with a piperazine substitution, inhibited angiogenesis induced by conditioned media (CM) from MDA-MB-231 cells under hypoxia and revealed its underlying mechanism. The results showed that LYG-202 decreased CXCL12 secretion and CXCR7 expression, leading to suppression of its downstream ERK/AKT/nuclear factor kappa B (NF-κB) signaling, which eventually decreased the expression of MMP-2, MMP-9, RhoA and increased VE-cadherin expression in EA.hy 926 cells treated with CM from MDA-MB-231 cells under hypoxia. The decreased migration ability, increased cell adhesion and inhibited CXCR7 pathway by LYG-202 could also be reproduced in human umbilical vein endothelial cells. More importantly, LYG-202 also inhibited tumor angiogenesis and tumor growth of human breast cancer MDA-MB-231 cells in nude mice through CXCL12/CXCR7 pathway. In summary, LYG-202 is a potential agent to prohibit tumor angiogenesis through inhibiting the activation of endothelial cells.
Introduction
Breast cancer is the most fatal tumor in women worldwide (1) . It is now widely accepted that both the growth and metastasis of breast cancer require tumor angiogenesis (2) . Although Bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), has taken for the treatment of metastatic breast cancer, triple-negative breast cancer (TNBC), which has been characterized as a negative expressing of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2, it is still with poor treatment outcome and did not improve disease-free survival in unselected TNBC patients (3, 4) . Therefore, it is imperative to develop new antiangiogenic therapies.
Angiogenesis is a process in which new blood vessels are formed from pre-existing ones and plays a vital role in cancer progression (5, 6) . It consists of many steps including proliferation of endothelial cells, invasion to extracellular matrix (ECM), migration to tissues, formation of new blood vessels and maturation of vessels (7) . Under normal circumstances, angiogenesis only occurs in menstrual periods, embryonic period and vascular injury (8) . However, angiogenesis also participates in the progress of numerous diseases such as tumor growth and metastasis (9) , inflammatory disorders (10), asthma (11) and diabetes (12) . During tumor progression, the balance of angiogenic switch is broken. Tumor cells secrete cytokines and chemokines to activate endothelial cells, enhancing their invasive and migratory ability. Activated endothelial cells move near to tumor cells and consequently cause the overgrowth of tumor vessels with characteristics to establish anoxic tumor microenvironment (13) . In turn, the tumor microenvironment under hypoxia will further induce angiogenesis by activating the key transcription factor, hypoxia-inducible factors-1α (HIF-1α), which promotes tumor progression with immune cell infiltration, metastasis and the supplement of nutrition (14) .
There are many proangiogenic cytokines and chemokines, such as VEGF, basic fibroblast growth factor (bFGF) and interleukin-8 (IL-8) (15) . Chemokines are a superfamily of small heparin-binding proteins that exert their bioactivity by binding to their corresponding receptors. According to the position of four conserved cysteine residues, they are divided into four subgroups (CXC, CX3C, CC and C) (15, 16) . Previous studies demonstrated that the CXC subgroup plays a pivotal role in angiogenesis in both physiological and pathological settings (17) (18) (19) . Of these factors, stromal-derived factor-1 (SDF-1 or CXCL12) accounts for the activation of endothelial cells. CXCL12 is a CXC chemokine that elicits its biological functions through binding to its receptor CXCR4 or CXCR7, thus stimulating proliferation, dissociation, migration and invasion in a wide variety of cells. The interaction between CXCL12 and CXCR4/7 also results in the activation of various downstream signaling cascades, including mitogen-activated protein kinases (MAPKs), PI3K/ AKT and NF-κB pathways (20) (21) (22) . As CXCL12 promoter contains two HIF-1α binding sites (23) , hypoxia in the solid tumors can induce the expression and secretion of CXCL12. Accumulating evidence reveals that membrane-associated CXCR7 is expressed in different types of tumor cells and activated endothelial cells (24) . Overexpression of CXCR7 and its activation in the vascular endothelium enhance its invasive and migratory ability towards tumor (25, 26) . Therefore, CXCL12/CXCR7 signaling plays a crucial role in tumor angiogenesis. Figure S1A is available at Carcinogenesis Online), a synthesized flavonoid with a piperazine substitution, was previously shown to possess an antitumor property both in vitro and in vivo. The proposed mechanism of LYG-202 involves induction of apoptosis and cycle cell arrest in tumor cells (27) . However, the administered dosage of LYG-202 in vivo was very high (750 mg/kg), though it causes no obvious side effects (28, 29) . So it is suspected whether LYG-202 works on tumor cells and reduces the size of tumors directly in vivo. Although one study reported that LYG-202 could inhibit VEGFinduced angiogenesis in vitro (30) , how LYG-202 inhibits tumor angiogenesis and whether inhibition of angiogenesis causes reduction of tumor are still unknown. In this study, we investigated the antiangiogenic effect of LYG-202. We demonstrated that LYG-202 inhibited the invasion and migration of endothelial cells induced by conditioned medium (CM) from MDA-MB-231 cells under hypoxia condition. Furthermore, we uncovered that CXCL12/CXCR7 biological axis is crucial for the activation of endothelial cells under hypoxia. Our results suggest that the intervention of this process by LYG-202 is a promising therapeutic strategy for the treatment of the TNBC.
LYG-202 (Supplementary

Materials and methods
Reagents
LYG-202 was obtained from Z.L. (China Pharmaceutical University, China). The structure of LYG-202 was identified using IR, 1H-NMR, MS and elemental analysis. The crude products were purified by flash chromatography (ether petrol/AcOEt = 50:50). The purity was determined by HPLC (70:30 methanol:water with 1‰ TFA): tR = 8.1 min, 99.62%, mp: 292-294°C. LYG-202 was dissolved in DMSO to maintain a concentration of 10 mM as a stock solution, stored at −20°C. Before each experiment, LYG-202 stock solution was diluted with fresh DMEM medium to working solution. CoCl 2 is used to maintain HIF-1α expression, and it is obtained from Sigma (St. Louis, MO). Human Recombinant CXCL12 was purchased from Peprotech (Rocky Hill, NJ). Matrigel was purchased from BD Bioscience (San Jose, CA). Primary antibody for MMP-2, Rac1 and NF-κB was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Primary antibodies for ERK1/2, phosphor-ERK1/2, Akt, phosphor-Akt, IKKα, p-IKKα, IκB and p-IκB were purchased from Cell Signaling Technology (Danvers, MA). Primary antibodies for CXCR7, CXCR4, MMP-9, CD31, VE-cadherin and GAPDH were purchased from Bioworld Technology (St. Louis Park, MN). CXCL12 neutralizing antibody is purchased from LifeSpan BioSciences (Seattle, WA).
Animals
This experiment was approved by animal ethical committee of China Pharmaceutical University. Five-to six-week-old female BALB/c nude mice (Slaccas Shanghai Laboratory Animal Co., Ltd., Shanghai, China) were used for magrigel plug assay and xenograft of MDA-MB-231 cells. The animals were maintained in a pathogen-free environment (23 ± 2°C, 55 ± 5% humidity) on a 12 h light/12 h dark cycle with food and water supplied ad libitum throughout the experimental period.
Cell culture
Human permanent vascular endothelial cell line, EA.hy 926 and human breast carcinoma MDA-MB-231 cells were purchased from Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. Cells were grown in DMEM medium (Gibco, Grand Island, NY) containing 10% fetal calf serum (Gibco), 100 U/ml penicillin and 100 U/ml streptomycin and incubated in a humidified atmosphere containing 5% CO 2 at 37°C. Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cord veins by collagenase treatment. The harvested cells were grown in medium 199 (Gibco, Grand Island, NY) containing endothelial cell growth supplement (ECGS, 30 μg/ml; Sigma, St. Louis, MO), epidermal growth factor (EGF, 10 ng/ml; Sigma, St. Louis, MO), 20% fetal bovine serum (FBS, Gibco, Grand Island, NY), 100 U/ml penicillin and 100 U/ml streptomycin, pH 7.4. After 3-5 passages, HUVECs were collected for use in the experiments. CM was collected from the supernatant of MDA-MB-231 cells incubated under hypoxia (1% O 2 , 94% N 2 and 5% CO 2 ) for 24 h and CM was used for conditioned culture with EA.hy 926 cells or HUVECs in different experiments.
Cell viability assay
The colorimetric MTT assay was carried out to measure the effect of LYG-202 on cell viability of EA.hy 926 cells. In brief, EA.hy 926 cells were plated at a number of 1.5 × 10 4 cells per well in 96-well plates for 24 h. Control cells in the plates were given fresh DMEM (100 μl/well) containing 0.1% DMSO, whereas the other groups were exposed to CM containing various LYG-202. After incubation under hypoxia for 24 h, 20 μl of 5 mg/ml MTT was added to cells and cells were incubated for another 4 h. The absorbance was measured at 570 nm by a universal microplate reader (EL800, Bio-Tek Instruments). Cell viability assay was conducted five times. The invasion assay was performed as similar with chamber directional migration assay above except that the matrigel diluted by serumfree medium (1:8) was coated on the upper chamber of the transwells. After overnight incubation under hypoxia, the invasion cells were fixed, stained and counted using a microscope. Cell migration and migration assays were conducted five times.
Immunofluorescence staining of cytoskeleton
The assay was performed to estimate the effect of LYG-202 on cytoskeleton remodeling. In brief, EA.hy 926 cells were treated with CM containing LYG-202 (0 and 2 μM) or fresh DMEM under hypoxia as described above before being washed with PBS twice. Cells were fixed with 4% paraformaldehyde for 30 min and permeabilized for 10 min in 0.2% Triton X-100 on ice before being washed with PBS three times. Then the cells were incubated with 3% BSA for 2 h to block the nonspecific binding and were dealt with FITC-conjugated phalloidin (Sigma-Aldrich Co., 1:300 dilution for overnight). Then cells were washed with PBS for three times and stained with 4,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich Co.) for 15 min. Finally, the coverslips were photographed with a confocal laser scanning microscope (Olympus, Tokyo, Japan).
Tube formation assay
Tube formation assay was performed to evaluate the ability of forming capillary-like tubes in EA.hy 926 cells. In brief, matrigel was mixed with serum-free medium (1:1) and coated on the 96-well plate (90 μl per well) to solidify and polymerized at 37°C for 30 min. EA.hy 926 cells (1.5 × 10 5 cells/ml) were collected with serum-free medium after treatment with CM containing LYG-202 (0.5, 1 and 2 μM) or fresh DMEM under hypoxia for 24 h as described above and then cells seeded on the matrigel (200 μl per well). Eight hours later, tubular structures were counted using a microscope.
Rat aortic ring assay
Rat aortic ring assay was performed as described previously with some modification (31) .The thoracic aorta dissected from male Sprague-Dawley rats (6 weeks old) was cut into 1 mm long rings. Clotting media containing M199 + (M199 + with 100 U/ml penicillin and 100 U/ml streptomycin), 0.3% fibrinogen, and 0.5% ε-amino-n-caproic acid (ACA; Sigma, St. Louis, MO) were added to 24-well plates (800 μl per well) with thrombase to solidify after the rings were added to the well. Grown media containing M199 + (M199 + with 20% FBS and 0.5% ACA) were added to the well. One or two days later, the aortic ring starts to sprout, forming microvessel-like structures. On the third day, five rings were used as a group and the grown medium was replaced with 10% FBS medium or CM (CM with 100 μM CoCl 2 ) containing various concentrations of LYG-202 (0, 2, 4 and 8 μM) as indicated. Plates were then stored in an incubator at 37°C and 5% CO 2 . After 7 days, the microvessel was quantified by manually counting the number of microvessels from the rat aortic rings and photographed under a microscope for each group.
Chicken chorioallantoic membrane assay
Chicken chorioallantoic membrane (CAM) assay was performed to measure the inhibitory effect of LYG-202 on angiogenesis in vivo. Fertilized chicken eggs was incubated at 37°C for 9 days before punching a small hole on the broad side of the egg and creating a window on the eggshell. Sterilized filter paper disks filled with or without CM containing 100 μM CoCl 2 and LYG-202 (12.5, 25 and 50 ng/egg) were placed on CAMs and the eggs were stored in an incubator at 37°C and 5% CO 2 for another 2 days.
Then we injected the 10% fat emulsion (Intralipose, 10%) into the CAMs and photographed. Six eggs were used as a group and the number of newly formed vessels was quantified by manually counting.
In vivo Matrigel plug angiogenesis assay
Matrigel plug assay was performed as described previously with some modification (32) . In brief, MDA-MB-231 cells (3 × 10 6 ) were mixed with matrigel. BALB/c nude mice were injected subcutaneously with 0.6 ml of mixture or blank matrigel. The mice were administrated LYG-202 (100 mg/ kg) orally on day 1, 3, 5 and 7. On day 7, the mice were killed. The matrigel was removed and photographed. The surrounding tissues were discarded for hemoglobin contents check with Hemoglobin assay kit (BioChain Science and Technology, Beijing, China) according to the instructions.
Cytokines detected by ELISA
The concentration of cytokines (VEGF, bFGF, TNF-α, CXCL12) in supernatant from EA.hy 926 cells treated with CM and LYG-202 was detected by ELISA kit (Beyotime Biotechnology, Shanghai, China). Briefly, EA.hy 926 cells were plated at a number of 3 × 10 5 cells per well in 6-well plates for 24 h. The EA.hy 926 cells were treated with CM containing LYG-202 or fresh DMEM under hypoxia for another 24 h as above. Then, the supernatant diluted with sample diluent buffer was added to the microwell (100 μl/well) and the plates were then stored in an incubator at 37°C for 90 min. The supernatant was discarded and antibody diluted with antibody diluent buffer was added to the microwell (100 μl/well) and stored in an incubator at 37°C for 1 h. Then plates were washed with PBS for three times and AvidinBiotin-Peroxidase-Complex (ABC) diluted with ABC diluent buffer was added to the microwell. After incubated at 37°C for 30 min, ABC was discarded and plates were washed with PBS for five times. Add the TMB color developing agent to the microwell (90 μl/well) at 37°C for 20 min and then add the TMB stop solution (100 μl/well). The absorbance was measured at 450 nm using a universal microplate reader (EL800, Bio-Tek Instruments).
Gelatin zymogram
Gelatin zymography was performed as described previously using matrix metalloproteinase (MMP) Zymography Assay Kit (SIGMA AMRESCO TAO, Shanghai, China) (33) . Briefly, the EA.hy 926 cells were incubated with CM or fresh DMEM and treated with LYG-202 (0.5, 1 and 2 μM) under hypoxia for 24 h before the supernatants were collected. SDS-PAGE gels were prepared containing copolymerized gels including 1 mg/ml of gelatin. After electrophoresis, the gels were washed with buffer A for 30 min twice. Then the gels were incubated in buffer B at 37°C for 24 h. The gels were stained with 0.1% Coomassie Brilliant Blue R-250 and destained with 10% acetic acid and 10% methanol. Enzyme-digested regions were appeared as white bands and the gels were photographed using the GeneGenius Image and Analysis System (Syngene, Cambridge, UK)
Western blotting analysis
The total protein was extracted using lysis buffer (25 mM Tris•HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 0.2 mmol/l PMSF, 0.1 mmol/l NaF and 1.0 mmol/l DTT). Add the lysis buffer to the cells and keep on ice for 1 h. Then the lysates were centrifuged at 12 000 rpm for 30 min and the protein concentration in the extracts was detected with BCA protein assay and denatured with sodium dodecylsulfate sample buffer. The SDS-PAGE gels were prepared and the proteins were then transferred to nitrocellulose membranes which were saturated with 1% BSA in PBS. The blots were incubated with specific antibodies (diluted 1:1000) against indicated primary antibodies overnight at 4°C followed by IRDye™ 800 conjugated secondary antibody for 1 h at 37°C. Detection was performed using the Odyssey Infrared Imaging System (LI-COR, Lincoln, NE).
siRNA transfection
EA.hy 926 cells were seeded at 3.0 × 10 5 cells/well in six-well plates for 24 h before transfection. Transfection was performed according to the manufacturers' instructions (SuperFectinTM II In-Vitro siRNA Transfection Reagent; Shanghai Pufei Biotech, Shanghai, China). EA.hy 926 cells transfected with a scrambled siRNA were used as controls. Then, EA.hy 926 cells were exposed to CM containing LYG-202 (0, 0.5, 1 and 2 μM) under hypoxia for 24 h.
Real-time PCR analysis
EA.hy 926 cells were harvested after being treated with LYG-202 as described above. Total RNA from EA.hy 926 was extracted using Trizol reagent (Invitrogen, Carlsbad, CA) according to the instructions. Reverse transcription reaction from TaKaRa PrimeScript RT reagent Kit was used, 1 μl of cDNA, 0.5 μl each forward and reverse primers, 8 μl distilled water (ddH 2 O) and 10 μl of TaKaRa SYBR Premix Ex Taq™ (2×) with 0.4 μl Rox Reference Dye II (50×). The sequence of primers used were as follows: human MMP-2, forward primer, 5′-GAC AAC GCC CCC ATA CCA G-3′, and reverse primer, 5′-CAC TCG CCC CGT GTG TTA GT-3′; human MMP-9, forward primer, 5′-ACGCAG ACA TCG TCA TCC AGT-3′, and reverse primer, 5′-GGA CCA CAACTC GTC ATC GTC-3′; human β-actin, forward primer, 5′-CTG TCCCTG TAT GCC TCT G-3′, and reverse primer, 5′-ATG TCA CGC ACGATT TCC-3′. The optimal PCR condition was carried out according to previous instructions (34) .
Immunofluorescence staining of CD31
Tumor tissue sections (4 mm thick) were placed onto treated slides (Vectabond, Vector Laboratories, Burlingame, CA). Sections were heat fixed, deparaffinized and rehydrated through graded alcohols (100, 95, 85, 75%) to distilled water. Tissue sections were boiled in citrate buffer at high temperature for antigen retrieval and treated with 3% blocking buffer containing 5% goat serum and 0.5% BSA. Tissue sections were incubated with primary antibodies (diluted 1:50) against CD31, which was done overnight at 4°C. The tissues were then incubated with the secondary fluorescein-labeled antibody (diluted 1:200) for 1 h and incubated with the fluorochrome dye DAPI (Santa Cruz Biotechnology) for nuclei. Samples were observed and captured with a confocal laser scanning microscope (Olympus Corp., Tokyo, Japan).
Tumor growth of MDA-MB-231 cells in nude mice
MDA-MB-231 cells (1 × 10 7 ) were injected into female BALB/c nude mice for about 2 weeks until the original formation of tumor. Then the mice were equally distributed into five groups (with six mice per group) randomly: saline control group, paclitaxel (8 mg/kg) group, LYG-202 (50 mg/kg) group, LYG-202 (100 mg/kg) group, and LYG-202 (200 mg/kg) group, respectively. Mice were treated with LYG-202 by gavage or paclitaxel by intravenous injection every 2 days. The weight, tumor width (W) and Length (L) were measured by an average of 3 days. The tumor volume (V) was estimated with the following formula: V = 1/2 × L × W 2 . In addition, mice were killed 3 weeks later after treatment and the tumor was weighed.
Statistical analysis
All results were presented as mean ± SEM. All data from each experiment were gained in at least three independent experiments. Statistical analyses were performed using one-way analysis of ANOVA using SPSS 11.5 software. All comparisons are made relative to CM-treated group, CXCL12 antibody-treated group, CXCR7 siRNA-treated group or CXCL12-induced group. The significance of difference is indicated as *P < 0.05 and **P < 0.01. The migration and invasion of endothelial cells to the basement membrane are two important steps in formation of the new capillary tubes (35) . Transwell assay was performed to test the effect of LYG-202 on migratory and invasive ability of EA.hy 926 cells induced by MDA-MB-231 cells under hypoxia. As shown in Figure 1A 
Cell line authentication
The inhibitory rate of migrated/invasive cells was reduced by 37.2%, 58.8% and 74.9%/27.1%, 50.7% and 70.1%, respectively.
To observe the dynamic motility of EA.hy 926 cells in the conditioned culture system, time-lapse video imaging was used to demonstrate the inhibitory effect of LYG-202 on the migration of EA.hy 926 cells. As shown in Figure 1C , arrows with the same color in different time points group labeled the same cell. The instant position of the individual cell and the migratory distance was quantitated in Supplementary Material (Supplementary Figure S1C is available at Carcinogenesis Online). We found that CM increased the migration distance of EA.hy 926 cells under hypoxia while the pseudopodium appeared gradually. In contrast, LYG-202 reduced the migration distance and inhibited the formation of pseudopodium of EA.hy 926 without suppressing proliferation. These results all suggested that LYG-202 could inhibit the migration and invasion of endothelial cells induced by breast cancer cells in vitro.
Cytoskeleton remodeling and stress fibers formation are essential for proteolytic interstitial cell migration (36) . Immunofluorescence staining of F-actin was analyzed with confocal microscopy imaging. As shown in Figure 1D , F-actin localized mainly at the cell periphery under normal conditions; meanwhile, the cytoplasmic stress fibers could not form markedly under hypoxia conditions. However, F-actin became less prominent and the cytoplasmic stress fibers obviously formed in EA.hy 926 cells induced by CM under hypoxia. In contrast, stress fibers of the cells treated with LYG-202 (2 μM) were reduced in comparison with the CM-induced group.
LYG-202 inhibited angiogenesis in breast cancer under hypoxia in vitro and in vivo
Since endothelial cell invasion is a key step of angiogenesis (37) and LYG-202 could potentially inhibit this process, tube formation assay was performed to evaluate the in vitro antiangiogenic activity of LYG-202. As shown in Figure 2A , the formation of capillary-like tubes was enhanced in CM-induced group than that of the normal group. However, the number of tubes was reduced in a concentration-dependent manner when various concentrations of LYG-202 (0.5, 1 and 2 μM) were added to the conditioned culture system and the inhibitory rates were 32.3%, 59.8% and 77.1%, respectively.
The process of sprouting in angiogenesis can be imitated in the model of rat aortic ring assay. CM containing 100 μM CoCl 2 was used as growth media to mimic the hypoxia in comparison with normoxia group. As shown in Figure 2B , LYG-202 inhibited the sprouting of microvessels in rat aortic ring induced by CM treated with CoCl 2 . This result indicated that LYG-202 could inhibit the formation of microvessel outgrowth in a concentration-dependent manner.
To evaluate the effect of LYG-202 on angiogenesis in vivo, we further used CM containing 100 μM CoCl 2 to mimic the hypoxia in the CAM assay. As shown in Figure 2C , eggs induced by CM treated with CoCl 2 were full of new blood vessels. However, the formation of new blood vessels was inhibited in a concentration-dependent manner when eggs were treated with LYG-202 (12.5, 25 and 50 ng/egg). The inhibitory rates were 14.1%, 42% and 71.6%, respectively, compared with CM-induced group.
Matrigel plug assay was then performed to further evaluate the antiangiogenic function of LYG-202 in vivo. As shown in Figure 2D , matrigel mixed with MDA-MB-231 cells promoted the formation of new blood vessels compared with the blank matrigel, but LYG-202 inhibited this angiogenic progress induced by breast cancer cells. Meanwhile, the concentration of hemoglobin in LYG-202-treated group was decreased by 32% compared with MDA-MB-231 cells-induced group while its concentration in the blank group was not detectable ( Figure 2E ).
All the results above suggested that LYG-202 may exert an antiangiogenic activity in breast cancer and it is closely related to the inhibition of migration and invasion of endothelial cells. 
LYG-202 decreased CXCL12 secretion and CXCR7 expression
ECM is a natural barrier between tumor cells and pre-existing blood vessel (38) . In the tumor microenvironment, the first step of angiogenesis is to degrade the ECM by MMPs and then activate endothelial cells from quiescent stage to activated stage in which the migratory and invasive ability is enhanced. Therefore, western blot assay was performed to evaluate the expression of proteins associated with cell migration and invasion. As shown in Figure 3A , the protein levels of MMP-2, MMP-9 and RhoA were increased in EA.hy 926 cells induced by CM under hypoxia compared with the normal or hypoxia group. LYG-202 inhibited their expression while increased VE-cadherin expression. LYG-202 also reduced the protein activity of MMP-2 and MMP-9 secreted in supernatant, as shown by Gelatin Zymogram assay ( Figure 3C ). These results suggested that LYG-202 not only affected MMP-dependent invasion but also increased cell-cell connection in endothelial cells.
To further investigate which cytokines affect the migration and invasion of endothelial cells in the conditioned culture system, ELISA assay was performed. As shown in Supplementary Figure S1E , available at Carcinogenesis Online, we discovered that the contents of VEGF and CXCL12 in the conditioned culture system were up regulated compared with normal or hypoxia group. However, LYG-202 dramatically inhibited the secretion of CXCL12 in the conditioned culture system but had no obvious effect on the contents of VEGF, bFGF and TNF-α. The results suggested that CXCL12 may play a key role in the migration and invasion of endothelial cells regulated by LYG-202. Further study on the expression of receptors of CXCL12 and its downstream signaling was carried out by western blot analysis. The expression of CXCR7 was enhanced in the conditioned culture system, whereas the CXCR4 expression did not change. Further molecular docking showed that LYG-202 could not be an antagonist of CXCR4 because LYG-202 could not bind with the amino acids CYS186, TRP94 and TYR116, which are important for the inactivation of CXCR4 (39) . Therefore, we focused on CXCR7 in this study and found that LYG-202 inhibited the expression of CXCR7. In addition, the phosphorylation of ERK1/2 and AKT were reduced, indicating that LYG-202 may block ERK1/2 and AKT signaling ( Figure 3B ). LYG-202 also inhibited the phosphorylation of IKK and IκB and restricted nuclear translocation of NF-κB p65 ( Figure 3D and E) . Thus, the up-regulated mRNA levels of MMP-2 and MMP-9 by CM under hypoxia, which could be regulated by the above transcriptional factors, were reduced by LYG-202 (Supplementary Figure S1D is available at Carcinogenesis Online).
In order to verify our hypothesis, we used the primary HUVECs which were isolated from human umbilical cord veins to detect the effect of LYG-202 on activation of endothelial cells. The decreased migration ability, increased cell adhesion and inhibition of CXCR7 pathway by LYG-202 could also be reproduced in HUVECs (Supplementary Figure S2A -C is available at Carcinogenesis Online). Meanwhile, the expression of MMP-2, MMP-9 and RhoA were also down-regulated and VE-cadherin expression increased by LYG-202, which are crucial biomarkers for invasion and cell adhesion (Supplementary Figure S2D and E is available at Carcinogenesis Online).
LYG-202 suppressed the CXCL12/CXCR7 axis to inhibit activation of endothelial cells
To confirm the significant roles of CXCL12/CXCR7 axis in the conditioned culture system, we blocked the interaction of CXCL12 with CXCR7 using CXCL12 neutralizing antibody. As shown in Figure 4A and B, CXCL12 antibody reduced the migration and invasion of cells, whereas LYG-202 could not strengthen these effects when CXCL12 antibody was added to the co-culture system. In tube formation assay ( Figure 4C ), we found similar results that LYG-202 could not further inhibit the formation of capillary-like tubes compared with the CXCL12 antibody-treated group in the conditioned culture system. These phenomena suggested that CXCL12 antibody could block the working of LYG-202. As shown in Figure 4D and E, western blot analysis proved that although LYG-202 could slightly reduce the expression of CXCR7 with CXCL12 antibody, it had little influence on the downstream ERK and AKT pathways, including effector proteins such as MMP-2, MMP-9, RhoA and VE-cadherin.
In the CXCL12/CXCR7 biological axis, the secretion of CXCL12 and the expression of CXCR7 are equally important (40) . As shown in Figure 5A , knockdown of CXCR7 with CXCR7 siRNA reduced its expression by nearly 60% in the conditioned culture system. In Figure 5B , LYG-202 did not inhibit CXCR7 expression as the low protein level reduced by CXCR7 siRNA. In Figure 5C , the function of LYG-202 on EA.hy 926 cells was blocked and its downstream proteins remained unchanged compared with the CXCR7 siRNA-treated group. Meanwhile, the results in Figure 5D -F demonstrated that decreased expression of CXCR7 led us to the decrease of migrated cells, invaded cells and finally the tubes in contrast with CM-induced group. However, with CXCR7 siRNA treatment, LYG-202 could not further inhibit the migration, invasion and tube formation in EA.hy 926 cells.
As LYG-202 inhibited the activation of endothelial cells in the conditioned culture system, CXCL12 recombined cytokine was used to test whether LYG-202 worked without MDA-MB-231 inducement. As shown in Supplementary Figure S3A 
LYG-202 inhibited tumor growth and angiogenesis of MDA-MB-231 cells in vivo
Angiogenesis is a central player in regulating the development of tumor growth, invasion and metastasis. Previous reports have demonstrated that CXCL12 and CXCR7 were overexpressed in breast cancer tissues compared with normal breast tissues (25, 41) .
To further evaluate the mechanism of LYG-202 in breast cancer, we transplanted the MDA-MB-231 cells in BALB/c nude mice. The mice were administrated with LYG-202 (50, 100 and 200 mg/ kg) by gavage with paclitaxel (8 mg/kg) by intravenous injection. As shown in Figure 6A and B, the results indicated that LYG-202 inhibited the growth of MDA-MB-231 tumor in a dosage-dependent manner compared with the control group. The volume of tumor was reduced constantly and the inhibitory rates of LYG-202-treated group were 32.8%, 48.8% and 58.8%, respectively, whereas the inhibitory rate of paclitaxel-treated group (8 mg/kg) was 46%. Immunofluorescence staining of CD31 was carried out to detect the formation of new blood vessels in the breast tumor. The control group was filled with irregular and immature blood vessels, whereas the LYG-202 and paclitaxel-treated group have less coverage of new blood vessels ( Figure 6C ). Furthermore, western blot analysis revealed that LYG-202 also inhibited the expression of CXCR7 and the phosphorylation of ERK1/2 and AKT in vivo ( Figure 6D ). The expression of MMP-2, MMP-9, RhoA and VE-cadherin in vivo was also regulated in a dosage-dependent manner ( Figure 6E ), which suggested that LYG-202 inhibited tumor growth and angiogenesis through blocking CXCL12/ CXCR7 axis.
Discussion
In the initial phase of tumor development, the diameter of tumor is <1-2 mm without new blood vessel formation (42) . To acquire extra supplement of nutrient, tumor cells secrete cytokines and chemokines to activate the endothelial cells and initiate the process of angiogenesis. In contrast with normal endothelial cells, activated endothelial cells form more filopodia and lamellipodia to regulate contraction and protrusion which rely on actin cytoskeleton remodeling and ATP hydrolysis. Activated endothelial cells also dramtatically enhance their migration and invasive ability compared with normal ones. Therefore, the activation of endothelial cells was a key step in tumor angiogenesis. Hypoxia is one of the features of tumor microenvironment and activation of HIF pathway is increased from outer to inner. Here, tumor vessels are highly irregular, leaky and poorly functioning (43) . Ionizing radiation and chemotherapy are less effective due to lack of oxygen and poor drug delivery (44) . Therefore, therapeutic strategies of targeting angiogenesis should be revisted from starving tumors to alleviating hypoxia.
Previous studies of antiangiogenic therapy mainly focoused on VEGF/VEGFR pathway and its related targeted monoclonal antibodies or kinase inhibitor have obtained certain therapeutic effects in clinic, especailly in breast cancer. However, excessive suppression of angiogenesis results in hypoxic tumor microenvironment and increases possibility of metastasis. In contrast, inhibition of activated endothelial cells not only restrains angiogenesis, but also promotes normalization of tumor vessels, which thus potentially alleviate hypoxia, reduce peritumor edema and inhibit lymphatic metastasis (45) .
Our previous research has demonstrated that LYG-202 induced apoptosis in MDA-MB-231 cells (46) , but we could not detect the vast apoptotic cells in the xenografted tumors according to the subsequent experiments (data not shown). This might be due to the drug-resistance and stemness of MDA-MB-231 cells, and thus, LYG-202 could not induce apoptosis of MDA-MB-231 cells in vivo. Interestingly, LYG-202 could reduce VEGF-induced angiogenesis (47) and antiangiogenic therapy has been proved clinically effective in TNBC (48) . Since in our preliminary experiment LYG-202 did not induce apoptosis of MDA-MB-231 cells in vivo, we investigated the effect of LYG-202 on endothelial cells instead of MDA-MB-231 cells in this study.
As apoptosis of endothelial cells might lead to hypoxia, to avoid the antiproliferative effect of LYG-202, we ultimately used the concentration of LYG-202 (0.5, 1 and 2 μM) in all experiments in vitro. EA.hy.926 cells (human permanent vascular endothelial cell line) were selected because it is difficult to obtain human umbilical cord veins and HUVECs are prone to differentiate after passages. HUVECs were also used to further vertify the antiangiogenic effect of LYG-202. Our results indicated that LYG-202 inhibited the migration, invasion, tube formation and cytoskeleton remodeling of EA.hy 926 cells in vitro and further inhibited the process of sprouting and angiogeneisis in vivo. To explore the mechanism of activation of endothelial cells by MDA-MB-231 cells, we performed ELISA assays in the conditioned culture system. We found that the secretion of CXCL12 is crucial for the activation of endothelial cells while LYG-202 blocks CXCL12/ CXCR7 axis in EA.hy 926 cells. CXCL12 was thought to play a key role in the process of invasion and metastasis of tumor cells. Consistent with previous reports, in this study, CXCL12/CXCR7 was shown to initiate the migration and invasion of endothelial cells in tumor environment. Inhibition of CXCL12/CXCR7 signaling by LYG202 resulted in decreased expression and secretion of MMPs, reduced degradation of ECM and enhanced endothelial cells connection through up-regulation of VE-cadherin, which is a significant biomarker of tumor vessel normalization.
CXCR7 has been shown to highly express in various human cancers, including lung, prostate, pancreas, HCC and breast cancer as well as tumor activated-endothelial cells. It was a signaling receptor and activate (MAPK) p42/44 and AKT phosphorylation by binding to its ligand. Therefore, inhibition of CXCR7 reduced the over-activation of ERK and AKT phosphorylation in activated endothelial cells. Our study demonstrated that CXCL12/CXCR4 axis and CXCL12/CXCR7 axis were both blocked by LYG-202 in EA.hy 926 cells through the decreased secretion of CXCL12. In addition, the increased expression of CXCR7 by breast cancer cells was decreased by LYG-202. Thus, the activation of CXCR4/ CXCR7 may also be inhibited and this further interfered the activation of multiple downstream pathways (49) (50) (51) . Indeed, their downstream signaling including ERK1/2 and AKT pathways was blocked by LYG-202, and the mRNA level of MMP-2, MMP-9 and VE-cadherin in EA.hy 926 cells was inhibited. When endothelial cells were treated with CXCL12 antibody or CXCR7 siRNA, the effect of LYG-202 on the migration and invasion was lost and the inactivation of CXCR7 signaling was not enhanced, suggesting that the inhibitory effect of LYG-202 was through the CXCL12/CXCR7 axis. In addition, LYG-202 could not suppress CXCR7 mRNA expression (data were not shown), so LYG-202 might affect the post-transcriptional processes. LYG-202 possibly occupied the binding region between CXCR7 and CXCL12, which prevented the integration of CXCR7 and CXCL12 and inhibited the activation of CXCR7. It was reported that MMPs expression is regulated by multiple transcription factors (52) . The results indicated that NF-κB was activated to promote the MMPs, VE-cadherin and RhoA expression via the phosphorylation of IKKα and degradation of IκB.
We used the matrigel plug assay and xenograft of MDA-MB-231 cells in BALB/c nude mice to evaluate the antiangiogenic and antitumor activity of LYG-202 in vivo. Considering that oral drug administration is more convenient and safer, we adopted gavage instead of intravenous injection to reduce the toxicity of LYG-202 and to promote the compliance in BALB/c nude mice. In matrigel plug assay, the MDA-MB-231 cells mixed with isometric matrigel were subcutaneously inoculated in the backside of mice and the dosage of LYG-202 (100 mg/kg) was determined by one-tenth of LD 50 (1000 mg/kg). We observed that the formation of new blood vessels and contents of hemoglobin were increased in MDA-MB-231 induced group and these effects were inhibited apparently by LYG-202. The results suggested that LYG-202 inhibits angiogenesis even without affecting the apoptosis of tumor cells. Next, we detected the inhibitory rate of the blood vessels by immunofluorescence staining of CD31. The results indicated that LYG-202 inhibited the formation of new blood vessels and ultimately inhibited the growth of tumor. Furthermore, western blot analysis showed that the LYG-202 inhibited the CXCL12/CXCR7 axis in tumor endothelial tissues and its effector proteins (MMP-2, MMP-9, RhoA and VE-cadherin) that associate with activation of endothelial cells also changed correspondingly.
In summary, our study convincingly demonstrated that LYG-202 suppresses the activation of endothelial cells and angiogenesis of breast cancer through inhibiting CXCL12/CXCR7 axis (Supplementary Figure S4 is available at Carcinogenesis Online). It expands our understanding of the angiogenesis process, supports normalization of tumor blood vessels as a novel therapeutic target and more importantly lays the foundation of developing LYG-202 as a promising therapeutic agent for the treatment of TNBC.
Supplementary Material
Supplementary Figures S1-S4 can be found at Carcinogenesis online.
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